Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2024-04-19 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
马应龙2024年第一季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled '2024年第一季度报告' which translates to '2024 First Quarter Report'. It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, and cash flow statements for the first quarter of 2024. The report explicitly states it is unaudited and includes comprehensive financial metrics and analysis for the quarter. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is about 15,000 characters long, indicating it is the full report rather than a brief announcement or certification. Therefore, the correct classification is IR with high confidence. Q1 2024
2024-04-19 Chinese
马应龙关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration certificate from the National Medical Products Administration. It details the drug's specifications, approval, and impact on the company. The document is short (1161 characters) and is an official announcement of a regulatory approval event, not a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report publication announcement since it is the announcement itself. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about a significant company event that does not fit other specific categories.
2024-04-16 Chinese
马应龙董事会审计委员会对会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the supervision of the accounting firm's audit duties for the fiscal year 2023. It discusses the appointment, qualifications, and performance of the audit firm, the audit scope, and the audit results including the issuance of an unqualified audit opinion on the 2023 financial statements. The document is focused on the audit committee's oversight and evaluation of the audit firm rather than the full annual report or the audit report itself. It is a standalone audit-related report describing the audit process and results, fitting the definition of an Audit Report / Information (AR). The document length is about 2058 characters, which is not extremely short, and it contains substantive content about audit supervision and evaluation, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-12 Chinese
马应龙关于为子公司提供贷款担保额度的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by 马应龙药业集团股份有限公司 regarding the provision of loan guarantees to its subsidiaries. It details the guarantee amounts, the subsidiaries involved, their financial status, and the board's approval of the guarantee proposal. The document includes specific financial figures related to guarantees but does not present comprehensive financial statements or a full financial report. It is a regulatory announcement about financing activities (loan guarantees) rather than a full financial report or earnings release. The content fits best under Capital/Financing Update (CAP) as it concerns updates on company financing activities and guarantees provided to subsidiaries.
2024-04-12 Chinese
马应龙2023年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度会计师事务所履职情况评估报告" which translates to "2023 Annual Evaluation Report on the Performance of the Accounting Firm." It details the qualifications, integrity, quality control, and audit procedures of the accounting firm engaged by the company for the 2023 fiscal year. The content focuses on the audit firm's performance and compliance with regulations rather than presenting the company's financial statements or audit opinions themselves. The document length is 2912 characters, which is relatively short and consistent with an evaluation or audit report rather than a full annual report or audit report. There is no indication that this is a full audit report or annual report, but rather an assessment of the auditor's performance. This fits the category of an Audit Report / Information (AR) as it relates to audit-related information but is not the full annual report or financial statements. FY 2023
2024-04-12 Chinese
马应龙关于申请银行综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the board of directors of 马应龙药业集团股份有限公司 regarding the application for a comprehensive bank credit facility totaling 8.9 billion yuan. It details the banks involved, credit limits, and terms. The document is short (791 characters) and focuses on financing activities, specifically the application for credit lines to support business operations. There is no financial statement or detailed financial analysis, nor is it a report or certification. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2024-04-12 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.